Sex matters at the NIH
decades, the norm in preclinical research has been to use male animals for in
vivo studies and ignore the sex of cells in in vitro studies for
reasons of cost and convenience. The NIH
wants to make the inclusion of both sexes the default in all preclinical studies and thinks the best way to alter
entrenched habits is by focusing on grants and publications.
Third Point says splitting Amgen will unleash value, but the portfolio shows the biotech is hard pressed to advance value-driving assets.
Amidst the rancorous debate over healthcare, Peter Reikes' experience reminds us what really happens to patients, and how much they depend on medical innovation.
Vasomune's peptidomimetic key activates Tie2 to treat acute kidney injury.
Unum's ACTR platform could generate T cell therapies that are safer and applicable to more cancers than those from competing platforms.
Novartis' Cosentyx could be the first IL-17 mAb to market, but it remains to be seen how much postmarket work FDA will require.
Molecular Partners postpones IPO on Swiss exchange. Plus: Investors' Tecfidera jitters; Biogen Idec's deal flow; NewLink's roller-coaster ride.
In the first lawsuit filed by an originator company over a biosimilars application, Amgen Inc. (NASDAQ:AMGN) alleged that the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) has unlawfully refused to follow the patent resolution protocol laid...
A new link between inflammation and atherosclerosis centers on the BET bromodomain protein BRD4 and could provide new targets for intervention.
The ALS Association is allocating the first funds from its ice bucket challenge to create four new research alliances that focus on genetics and biomarkers for the disease.
Bayer is emphasizing alliances rather than money to tap into Bay Area innovation.
The NIH is taking steps to make the inclusion of both sexes in preclinical studies a standard practice.
Preventing bone loss and consequent bone fractures with WNT16B therapy; enhancing brain levels of progranulin to treat AD; promoting repair of infection- or ischemia-induced tissue damage with compounds derived from human milk; and more...
Aptamer-mediated detection of monosaccharides and other low-epitope molecules to aid diagnostics development; transgenic Cas9 mice with CRIPSR-edited genomes as models of cancer; insulin-producing cells generated from human pluripotent cells to treat type 1 diabetes; and more...